- Home
- HYFM vs SYBX Comparison
HYFM vs SYBX Comparison
Compare HYFM & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- SYBX
- Stock Information
- Founded
- HYFM 1977
- SYBX N/A
- Country
- HYFM United States
- SYBX United States
- Employees
- HYFM N/A
- SYBX N/A
- Industry
- HYFM Industrial Machinery/Components
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- HYFM Industrials
- SYBX Health Care
- Exchange
- HYFM Nasdaq
- SYBX Nasdaq
- Market Cap
- HYFM 17.3M
- SYBX 16.4M
- IPO Year
- HYFM 2020
- SYBX N/A
- Fundamental
- Price
- HYFM $4.37
- SYBX $1.46
- Analyst Decision
- HYFM
- SYBX
- Analyst Count
- HYFM 0
- SYBX 0
- Target Price
- HYFM N/A
- SYBX N/A
- AVG Volume (30 Days)
- HYFM 7.7K
- SYBX 53.7K
- Earning Date
- HYFM 08-12-2025
- SYBX 08-07-2025
- Dividend Yield
- HYFM N/A
- SYBX N/A
- EPS Growth
- HYFM N/A
- SYBX N/A
- EPS
- HYFM N/A
- SYBX N/A
- Revenue
- HYFM $161,102,000.00
- SYBX N/A
- Revenue This Year
- HYFM $5.45
- SYBX N/A
- Revenue Next Year
- HYFM $5.33
- SYBX N/A
- P/E Ratio
- HYFM N/A
- SYBX N/A
- Revenue Growth
- HYFM N/A
- SYBX N/A
- 52 Week Low
- HYFM $1.50
- SYBX $0.90
- 52 Week High
- HYFM $8.55
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- HYFM 51.00
- SYBX 52.54
- Support Level
- HYFM $4.13
- SYBX $1.33
- Resistance Level
- HYFM $4.73
- SYBX $1.67
- Average True Range (ATR)
- HYFM 0.31
- SYBX 0.12
- MACD
- HYFM -0.03
- SYBX -0.01
- Stochastic Oscillator
- HYFM 45.18
- SYBX 38.24
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.